11 completed. 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 11 |
Follow Tinea Pedis: new trials by email Literature Review of Tinea Pedis trials Research Report on Tinea Pedis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis UHE-103 Cream, Naftin (naftifine hydrochloride) Cream - Tinea Cruris, Tinea Pedis | Phase 1 | Completed | Therapeutics, Inc. | 42 | 2022-02-17 | 2024-04-10 |
| Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis Naftifine Hydrochloride Gel 2%, Naftin® Gel 2%, Placebo Topical Gel - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1519 | 2014-06-27 | 2018-09-06 |
| Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis Naftifine Hydrochloride Cream 2%, Naftin® (Naftifine Hydrochloride) Cream 2%, Placebo Topical Cream - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 890 | 2013-08-01 | 2017-05-09 |
| Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis Naftifine HCl Cream 1%, Naftin® (Naftifine HCl) Cream 1%, Placebo topical cream - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1053 | 2012-05-01 | 2014-05-06 |
| Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis Anti-fungal agent (Clotrimazole) loaded microcapsules, Placebo - Tinea Pedis | Phase 1 | Completed | Prof. Yuen Chun-Wah | 42 | 2012-01-01 | 2013-04-02 |
| Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis Butenafine Hydrochloride Cream, 1%, Lotrimin Ultra®, Butenafine Vehicle - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 707 | 2012-01-01 | 2017-05-05 |
| A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis Oxiconazole Nitrate Cream 1%, Oxiconazole Nitrate Cream 1% (Oxistat®), Placebo - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 661 | 2011-11-01 | 2014-01-22 |
| Cumulative Irritation Test AN2718, Sodium Lauryl Sulfate - Tinea Pedis | Phase 1 | Completed | Pfizer | 44 | 2008-10-01 | 2019-04-16 |
| Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis Butenafine cream 1% manufactured by Taro, Lotrimin Ultra (butenafine) 1%, Butenafine Vehicle manufactured by Taro - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 548 | 2008-06-01 | 2014-02-04 |
| A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP) W0027, Placebo - Tinea Pedis | Phase 1 | Completed | Stiefel, a GSK Company | 120 | 2007-07-01 | 2017-05-30 |
| Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis Placebo, Terbinafine Hydrochloride, Terbinafine - Onychomycosis/Onycholysis and Tinea Pedis | Phase 1 | Completed | NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | 56 | 2005-02-01 | 2008-06-05 |
Onycholysis (1) · Onychomycosis (1) · Tinea Cruris (1)
Bacterial Infections and Mycoses (11) · Dermatomycoses (11) · Foot Dermatoses (11) · Foot Diseases (11) · Infections (11) · Mycoses (11) · Pathological Conditions, Signs and Symptoms (11) · Pruritus (11) · Signs and Symptoms (11) · Skin Diseases (11) · Skin Diseases, Infectious (11) · Skin Manifestations (11) · Skin and Connective Tissue Diseases (11) · Tinea (11) · Dermatitis (1)
naftifine (4) · butenafine (2) · Clotrimazole (1) · Sodium Dodecyl Sulfate (1) · Tablets (1) · Terbinafine (1) · oxiconazole (1)
Sun Pharmaceutical Industries, Inc. (6) · NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) (1) · Pfizer (1) · Prof. Yuen Chun-Wah (1) · Stiefel, a GSK Company (1) · Therapeutics, Inc. (1)
United States (5) · Australia (1) · Belize (1) · Hong Kong (1)
Chun Wah M. Yuen (1) · David Gratton, MD (1) · Debra Breneman, MD (1) · Eduardo Tschen, MD (1) · Joseph Fowler, MD (1) · Lynda Spelman, MD (1) · Michael Freeman, MD (1) · Ming Q Lu, MD., Ph.D. (1) · Natalie Yantovskiy (1) · Peter Foley, MD (1) · Stephen Shumack, MD (1) · Steven Grekin, MD (1)